Biond Biologics

Company Overview

Snapshot

Founded in April 2016 by Tehila Ben Moshe and Ori Shilo, Biond Biologics operates with 11–50 employees. The company has raised $45 million across 4 funding rounds from 7 investors. In June 2026, Biond Biologics announced an investment from Guangzhou Sino-Israel Biotech Investment Fund (GIBF) and a collaboration.

Business overview

Biond Biologics is a biotechnology company focused on developing immunotherapies and an intracellular drug delivery platform for cancer and auto-immune diseases. The company utilizes biologics that target novel immune evasion mechanisms, identified through in-house research using real-world patient and tumor samples. Its technology includes an intracellular delivery platform designed to enable the targeting of intracellular elements previously considered undruggable, operating within the Pharmaceuticals and Immunology sectors.

Strategic signal

In October 2025, Biond Biologics announced the initiation of a Phase 2 study for BND-22 in combination with anti-PD-1 therapy. This advancement signals the company's progress in clinical development and its commitment to bringing novel immunotherapies to market, potentially expanding treatment options for cancer patients and validating its drug pipeline for investors.

Company Intelligence Q&A

What was a significant recent development for Biond Biologics?

In October 2025, Biond Biologics announced the initiation of a Phase 2 study for BND-22 in combination with anti-PD-1 therapy, marking a key milestone in its clinical development pipeline.

When did Biond Biologics secure its most recent investment?

In June 2026, Biond Biologics announced an investment from Guangzhou Sino-Israel Biotech Investment Fund (GIBF) and a collaboration.

What was the outcome of the Series C financing round?

In November 2021, Biond Biologics closed its Series C financing round, with participation from investors including.

What was a key partnership established by Biond Biologics?

In January 2021, Biond Biologics and Sanofi entered into a global licensing agreement for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor.

When did Biond Biologics begin dosing patients with BND-22 in a Phase 1 clinical trial?

In April 2021, Biond Biologics announced the first patient was dosed in a Phase 1 clinical trial of BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor.